

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/816,721	03/22/2001	Carsten Andersen	5347.210-US

CONFIRMATION NO. 6030

25908

NOVOZYMES NORTH AMERICA, INC.
C/O NOVO NORDISK OF NORTH AMERICA, INC.
405 LEXINGTON AVENUE, SUITE 6400
NEW YORK, NY 10174

FORMALITIES LETTER



OC000000006124307

Date Mailed: 05/29/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or email patin21help@uspto.gov or patin3help@uspto.gov




A copy of this notice MUST be returned with the reply.

A handwritten signature in black ink, appearing to be 'J. Smith', is written over a horizontal line.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY



Box Sequence Listing / 03C0

Attorney Docket No.: 5347.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al

Serial No.: 09/816721

Confirmation No: 6030

Group Art Unit: 1652

Filed: March 22, 2001

Examiner: To be assigned

For: Novel Cyclomalto-dextrin Glucanotransferase Variants

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Box Sequence
Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:


1. Response to Notice to Comply with Sequence Rules
2. Sequence Listing
3. Copy of Notice to Comply with Sequence Rules
4. Disk Containing Sequence Listing

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box Sequence
Commissioner for Patents
Washington, DC 20231

on July 30, 2001.

Kelley O'Patry
(name of person mailing paper)


(signature of person mailing paper)



#3

Attorney Docket No.: 5347.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al

Serial No.: 09/816721

Confirmation No: 6030

Group Art Unit: 1652

Filed: March 22, 2001

Examiner: To be assigned

For: Novel Cyclomaltoextrin Glucanotransferase Variants

**AMENDMENT AND RESPONSE TO NOTICE TO FILE MISSING PARTS
AND TO NOTICE TO COMPLY WITH SEQUENCE RULES**

Box Sequence
Commissioner for Patents
Washington, DC 20231

Sir:


In response to the Notice to Comply with Sequence Rules dated May 29, 2001, please amend the above-captioned application as follows:

Applicants enclose herewith the Sequence Listing for the above-captioned application. The computer-readable form in this application is identical with that filed in Application Serial No. 09/158,216, filed September 22, 1998. In accordance with 37 CFR 1.821(e), please use the last filed computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. The content of the attached paper entitled "SEQUENCE LISTING" and of the diskette filed in the parent application is the same. Furthermore, the information contained in the attached "SEQUENCE LISTING" and the ASCII-encoded file is identical to the information in the specification as originally filed. This submission contains no new matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: July 30, 2001



Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123